RUNX1T1 and acute myeloid leukemia: (15) showed that diverse cooperating mutations may influence CBF-AML pathophysiology as well as clinical behavior and point to potential unique pathogenesis of t(8;21) vs. inv(16) AML, our study looks at AML-ETO patients in general, with an emphasis on the gene mutational landscape and the risk score combined clinical and molecular profiles, which can be a prognosis suggestion for AML-ETO patients.